Skip to content
Careers
Contacts
Menu
Close
Profile
About Transgene
Management Team
Board of Directors
Scientific advisors
Corporate governance
Ethics & compliance
Collaborations
Partners
Technology
Viral-based Immunotherapies
Individualized neoantigen cancer vaccines
Shared antigens cancer vaccines
Oncolytic Viruses
myvac Platform
Invir.IO Platform
Publications and Presentations
Portfolio
Pipeline
TG4050
TG4001
TG6050
BT-001
Clinical trials FAQ
Investors
Financial Information
Stock Information
Investor Events & Presentation
Annual General Meeting
Press Releases
€50.7 Million in Cash and Cash Equivalents as of March 31, 2017
20170425 PR Q1-2017